Internships at Takeda

About Takeda

Takeda is unlocking a new era of impact guided by a storied history of transformation and values-driven performance that has defined us for more than two centuries since our founding in Japan in 1781. Our vision is to discover and deliver life-transforming treatments. Grounded in our values, we put patients first, build trust, enhance our reputation and grow the business sustainably. We strive for collective success, are candid and embrace diverse perspectives, and move at pace against ambitious goals. A new first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV) marks an important milestone for the PV community and reflects significant progress for people living with this chronic blood cancer. A new chapter for narcolepsy type 1 (NT1) care and orexin science Discovery of this new class of medicine now approved in Japan was spearheaded by Takeda in the company’s labs in Shonan. We expect to make this first-in-class medicine available to the NT1 community by November 2026, pending U.S. Drug Enforcement Administration scheduling. Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

More from Takeda